Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines.
Korro's mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.
Korro Bio was founded in 2018 by Atlas Venture. The company is headquartered in Cambridge, Massachusetts.
Korro’s proprietary and modular platform, OPERATM, combines data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing.
Korro's unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety, in a cost-effective drug product.
Korro’s portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases.
Korro is backed by Wu Capital, Eventide Asset Management, Fidelity Management & Research Company, Atlas Ventures, NEA, Qiming Venture Partners, Surveyor Capital, Invus, Point72, Cormorant Asset Management, Alexandria Venture Investments, and others. The company completed a $116M Series B round on Jan 05, 2022. This brings Korro's total funding to $207.5M to date.